France pegs Gilead hepatitis C drug at "lowest price in Europe"
November 20, 2014 at 08:20 AM EST
PARIS, Nov 20 (Reuters) - France has negotiated a big discount for Gilead Sciences Inc's controversial new hepatitis C drug Sovaldi, under a government deal that ensures it will be fully reimbursable by health-funding schemes.
